Spanish Renewable Energy Stock News

Almirall has expanded its collaboration with the Barcelona Supercomputing Center to advance research in medical dermatology using supercomputing and artificial intelligence. The company has joined the BSC Connects program, gaining access to advanced computational tools, research support, and tailored training. The development focuses on strengthening Almirall’s dermatology R&D pipeline and future drug discovery capabilities. For investors tracking BME:ALM, the company is trading at €13.08...

Vivenio Residencial SOCIMI (BME:YVIV) has put fresh numbers on the table for FY 2025, reporting first half revenue of €37.7 million and basic EPS of €0.064. The trailing twelve months show revenue of €69.5 million and EPS of €0.121 on a share price of €1.35. The company has reported revenue of €28.1 million and EPS of €0.053 in the first half of 2024, followed by €31.8 million in revenue and EPS of €0.057 in the second half. This sets up FY 2025 with a results profile where investors may...

Hispanotels Inversiones Socimi (BME:YHSP) has put fresh numbers on the table for FY 2025, with the latest half year showing total revenue of €4.8 million and basic EPS of €0.38, set against a reported 45.8% earnings growth over the last 12 months. Over that period, revenue has moved from €8.5 million in the trailing twelve months to mid 2023 to €8.8 million in the latest trailing snapshot, while EPS has shifted from €0.59 to €0.85. This gives investors a clearer run of recent performance to...

The European stock market has recently experienced a notable upswing, with the pan-European STOXX Europe 600 Index rising by 3.05% amid improved investor sentiment following geopolitical developments. Despite this positive momentum, economic uncertainties persist, such as potential stagflationary pressures and revised growth forecasts by the EU. In this environment, identifying stocks that may be undervalued can present opportunities for investors seeking to capitalize on market...

As European markets experience a rally, buoyed by geopolitical developments and investor optimism, the region's growth companies are drawing attention for their potential amid shifting economic forecasts. In this context, stocks with high insider ownership can be particularly appealing as they often reflect management's confidence in the company's long-term prospects and alignment with shareholder interests.

As European markets rally amid easing geopolitical tensions, investors are increasingly looking towards dividend stocks as a stable source of income in an uncertain economic environment. In light of recent market movements, a good dividend stock is often characterized by consistent payouts and the ability to weather economic fluctuations, making them an attractive option for those seeking reliable returns.

In early April 2026, Banco Santander, S.A. completed several US dollar bond issues, including US$400 million of floating‑rate notes due 2029 and US$3.25 billion of fixed‑rate senior and non‑preferred notes maturing between 2029 and 2036, all issued at around par and featuring callable, unsecured, unsubordinated structures. Over roughly the same period, the bank disclosed that it has invested about €2.7 billion in an ongoing share buyback programme, retiring around 16.8% of its 2021 share...

Readers hoping to buy Naturhouse Health, S.A. ( BME:NTH ) for its dividend will need to make their move shortly, as the...

Pharma Mar (BME:PHM) just received a long term credit rating upgrade to BBB with a stable outlook, a shift that could influence how you view its funding options and growth capacity. See our latest analysis for Pharma Mar. The rating upgrade lands at a time when momentum in the share price is already strong, with a 30 day share price return of 17.97% and a year to date share price return of 21.60%. The 3 year total shareholder return of 130.23% points to a materially different experience for...

Grifols (BME:GRF) has drawn fresh attention after its H1 2025 update, reporting €3.7b in revenue, higher adjusted EBITDA, reaffirmed full year guidance, a stronger free cash flow outlook and a reinstated interim dividend. See our latest analysis for Grifols. Despite the solid H1 2025 update, the share price has had a weak run, with a 30 day share price return of 5.72% and a 90 day share price return showing a 21.56% decline, while the 1 year total shareholder return of 15.18% reflects a...

CIE Automotive has recently informed regulators that it will put to shareholders a supplementary dividend of €0.47 gross per share for the 2025 financial year, on top of an interim dividend of the same amount already paid, with payment scheduled for 7 July 2026 if approved and excluding treasury shares. This move, alongside a proposed Rs 7 per share dividend at CIE Automotive India, highlights the group’s current emphasis on cash returns and shareholder-focused capital allocation. With CIE...

Banco Santander (BME:SAN) is advancing its US bank merger with Webster Bank, setting out a new management structure for the combined business. The second tier of leadership for the merged Santander Webster entity has been announced, including new heads for commercial, retail, and digital banking. Swati Bhatia, who has held leadership roles at Santander's Openbank and US retail operations, will leave the group as part of these changes. The reshaping of leadership around the Santander Webster...

The European markets have seen a positive shift, with the STOXX Europe 600 Index rising by 3.92% amid hopes of a shorter-than-expected Middle East conflict. As investors navigate this evolving landscape, penny stocks—despite their somewhat outdated moniker—remain an intriguing segment for those seeking potential growth opportunities at lower price points. These smaller or newer companies often offer unique value propositions, and when supported by strong financials, they can present...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Miquel y...

Capital reduction and what it means for Endesa shareholders Endesa (BME:ELE) has moved ahead with a capital reduction, cancelling 17 million treasury shares under its Share Buyback Programme and adjusting total share capital to about €1.25b. This cancellation reduces the number of shares in circulation to just over 1b. This change can influence metrics such as earnings per share and ownership concentration once the capital reduction is formally registered. See our latest analysis for...

Recent share performance and what it might mean for investors Almirall (BME:ALM) has caught investor attention after a recent move in its share price, with a 2.4% gain over the past day and a 3.2% rise over the past week. Over the past month, the stock shows a 6.5% return, while the past 3 months reflect a 3.5% decline. This gives investors a mixed short term picture to weigh against longer term performance. See our latest analysis for Almirall. Zooming out, the recent strength in the share...

Banco Santander stock snapshot after recent share performance Banco Santander (BME:SAN) has drawn fresh attention after a strong recent run, with the share price showing positive moves over the past week, month and past 3 months, alongside solid reported revenue and net income figures. See our latest analysis for Banco Santander. At a share price of €10.46, Banco Santander’s recent 10.47% 1 month share price return sits alongside a 1 year total shareholder return close to 100%, suggesting...

Wondering if Telefónica at €3.90 is offering genuine value or just looks cheap on the surface? This article walks through the key clues in the current share price so you can judge that for yourself. The stock has returned 2.5% over the past week, 8.8% over 30 days, 12.0% year to date and 6.5% over the last year, with longer term returns of 15.1% over 3 years and 42.6% over 5 years. Recent coverage of Telefónica has focused on its position in European telecoms, its capital allocation choices...

Investors may be wondering whether Repsol is still attractively priced after its latest run, or if most of the easily accessible value has already been realized. The stock last closed at €22.57, with a 7.6% return over 30 days, 37.5% year to date, 149.4% over 1 year, 91.8% over 3 years, and 173.1% over 5 years. Over the most recent 7 days, the share price has declined by 3.4%. Recent headlines around Repsol have focused on broader sector sentiment and company-specific developments that...

Repsol reported past Q2 2025 adjusted income of €702 million, an 8% quarter-over-quarter increase, with operating cash flow rising 50% to €1.70 billion despite a €175 million EBIT impact from Iberian power outages. The company also reaffirmed its full-year guidance for €6.00 billion in operating cash flow, signalling management’s confidence in cash generation even after recent disruptions. We’ll now examine how this reaffirmed €6.00 billion operating cash flow guidance could influence...

Why Repsol’s latest results and board actions matter for shareholders Repsol (BME:REP) has drawn fresh attention after Q2 2025 adjusted income reached €702 million and operating cash flow came in at €1.7 billion, alongside a board meeting to consider calling the Annual General Meeting. For you as a shareholder or potential investor, the combination of higher adjusted income, stronger cash generation and an upcoming AGM sets the stage for decisions on capital allocation, dividends and the...

It looks like Banco Bilbao Vizcaya Argentaria, S.A. ( BME:BBVA ) is about to go ex-dividend in the next three days. The...

If you are wondering whether Banco Santander's share price still offers value, you are not alone. This article walks through the numbers behind that question. The stock last closed at €9.81, with returns of 3.6% over 7 days, 2.1% over 30 days, a year-to-date return of a 4.3% decline, 67.0% over 1 year and very large gains over 3 and 5 years. Recent coverage has focused on Banco Santander's strong share price performance over the last year and the scale of its multi-year gains, which has put...

Almirall, S.A. recently reported positive long-term interim Phase 3b ADlong results for lebrikizumab in moderate-to-severe atopic dermatitis, showing sustained efficacy and a consistent safety profile over up to four years, at the American Academy of Dermatology meeting in Denver. The data, including high rates of near-complete skin clearance and itch relief mostly achieved without topical corticosteroids, underline lebrikizumab’s potential to anchor Almirall’s European dermatology franchise...